Catalyst

Slingshot members are tracking this event:

EyeGate Receives Additional Milestone Payment From Valeant Pharmaceuticals for EGP-437

Source Link:
http://www.eyegatepharma.com/press-release/eyegate-receives-additional-milestone-payment-from-valeant-pharmaceuticals-for-egp-437/

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
EYEG Community voting in process
VRX Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details EyeGate has received an additional development milestone from Valeant under the Company’s License Agreement with Valeant for the development and commercialization of the Company’s EGP-437 combination product in the field of uveitis.
http://www.eyegateph...
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Mar 02, 2016
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Egp-437, Milestone Payment, Uveitis
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.